[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.211.62.139. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
February 1987

Treatment of Cancer-Associated Hypercalcemia With Cisplatin

Author Affiliations

From the Sections of Medical Oncology (Drs Lad, Mishoulam, Shevrin, and Kukla) and Endocrinology (Drs Abramson and Kukreja), Department of Medicine, West Side Veterans Administration and University of Illinois Hospitals, University of Illinois College of Medicine, Chicago.

Arch Intern Med. 1987;147(2):329-332. doi:10.1001/archinte.1987.00370020147053
Abstract

• Cisplatin (cis-platinum) has been shown to lower cancerassociated humoral hypercalcemia in an animal model and to inhibit bone resorption in vitro. This prospective study was designed to evaluate the efficacy of cisplatin in treating cancer-associated hypercalcemia in humans. Thirteen patients with severe hypercalcemia refractory to rehydration were treated with a 24-hour infusion of cisplatin, 100 mg/m2. Serial measurements of serum calcium and tumor size were made following cisplatin treatment and compared with pretreatment values. Nine patients (69%) achieved normocalcemia after treatment with cisplatin; and mean duration of benefit was 38 days in these patients. No reduction in tumor size was seen. All patients died of progressive cancer. We conclude that cisplatin can control malignant hypercalcemia for relatively long periods, and that its mechanism of action is not due to a reduction in tumor size.

(Arch Intern Med 1987;147:329-332)

×